|This article is part of Infectious Disease Advisor’s in-depth coverage of IDWeek 2017™, which took place in San Diego, CA. Our staff will be reporting on the latest treatment advancements and research initiatives for skin infections. Check back regularly for highlights from IDWeek 2017.|
Patients with acute bacterial skin and skin structure infection (ABSSSI) experience a shorter infection-related length of hospital stay when treated with ceftaroline fosamil (CPT) vs vancomycin (VAN), according to findings from a retrospective study presented at IDWeek 2017, held October 4-8 in San Diego, California.
“Hospital visits for ABSSSIs are rising,” noted the investigators, “[and] inadequate treatment results in longer stays and increased recurrences. CPT is approved for ABSSSI, [al]though real-world clinical comparative data are limited.”
Investigators performed a retrospective, propensity-matched cohort study of patients with ABSSSI (N=311) who were treated with either CPT (n=119) or VAN (n=192). The researchers aimed to evaluate and compare the infection-related length of stay in both groups. Patients were included if they had ≥3 clinical signs that required ≥72 hours VAN or CPT initiated ≤120 hours after the diagnosis of ABSSSI.
The average infection-related length of stay in the entire cohort was 6 days. Comorbidities of patients in each group included peripheral vascular disorders (24%), chronic pulmonary disease (26%), and diabetes (38%).
Cellulitis, lower extremity, and methicillin-resistant Staphylococcus aureus comprised all ABSSSIs in the study population (54%, 48%, and 21%, respectively). Approximately 64% of subjects with ABSSSI were not required to undergo surgical treatment, and 55% were eventually able to switch from intravenous (IV) antibiotics to their oral form.
Overall, the median infection-related length of stay for patients treated with CPT was significantly lower than patients receiving VAN (5 vs 7 days, respectively; (P =.007). Investigators found that CPT was also associated with shorter infection-related length of hospital stay even after adjusting for the type of ABSSSI, among other factors (P =.013).
“Early CPT use may be considered for patients who need IV antibiotics for ABSSSI treatment to facilitate early discharge,” concluded the investigators. Additional studies are needed to confirm these findings.
|Visit Infectious Disease Advisor’s conference section for continuous coverage live from IDWeek 2017.|
Trinh TD, Zasowski EJ, Claeys K, et al. Ceftaroline fosamil (CPT) versus vancomycin (VAN) for acute bacterial skin and skin structure infections (ABSSSI). Presented at: IDWeek 2017; October 4-8, 2017; San Diego, California. Poster 1884.